Erratum: Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age (The Journal of Infectious Diseases (2013) 208:12 (1953-1961) DOI: 10.1093/infdis/jit365);Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age

Journal of Infectious Diseases

Volumn 208, Issue 12, 2013, Pages 1953-1961

  Chlibek, Roman ^a   Bayas, José M ^b   Collins, Harry ^c   De La Pinta, Maria Luisa Rodriguez ^d   Ledent, Edouard ^e   Mols, Johann F ^e   Heineman, Thomas C ^f  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b HOSPITAL CLÍNIC   (Spain)

^c MITSS   (United States)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e GSK   (Belgium)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; Immunogenicity; Recombinant subunit vaccine; Safety; Varicella zoster virus

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; RECOMBINANT VARICELLA ZOSTER GLYCOPROTEIN E VACCINE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; ADJUVANT; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CHILL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN REDNESS; TREATMENT RESPONSE; VACCINATION; VERY ELDERLY; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; MULTICENTER STUDY; RECOMBINANT SUBUNIT VACCINE; SAFETY; VARICELLA ZOSTER VIRUS; CLINICAL TRIAL;

ADJUVANT; IMMUNOGENICITY; RECOMBINANT SUBUNIT VACCINE; SAFETY; VARICELLA-ZOSTER VIRUS;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 84897122797     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiaa560     Document Type: Erratum

References (21)

1. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epide-miology of herpes zoster. J Clin Virol 2010; 48(Suppl. 1):2-7.
2. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8.
3. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
4. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008; 364:272-80.
5. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503.
6. Grose C. Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol 1990;44:59-80.
7. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996; 9:361-81.
8. Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and mono- therapeutic agents. Expert Opin Biol Ther 2004; 4:1129-38.
9. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991; 146:431-7.
10. Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471-86.
11. + T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. Vaccine 2012;31:2196-206.
12. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell- mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012; 30:3126-35.
13. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280-90.
14. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices Centers for Disease C, Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4.
15. Moris P, van der Most R, Leroux-Roels I, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54.
16. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152:522-31.
17. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35.
18. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl I Med 2002; 347:26-34.
19. Weinberg A, Zhang JH, Oxman MN, et al Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-77.
20. Haberthur K, Engelmann F, Park B, et al. CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS pathogens 2011; 7:e1002367.
21. McElhaney JE. Prevention of infectious diseases in older adults through immunization: The challenge of the senescent immune response. Expert Rev Vaccines 2009; 8:593-606.